MeSH term
Frequency | Condition_Probility | Female | 4 | 0.0 |
Humans | 20 | 0.0 |
Immunoblotting | 3 | 0.0 |
Immunohistochemistry | 2 | 0.0 |
Male | 2 | 0.0 |
Nuclear Pore Complex Proteins/*metabolism | 2 | 15.0 |
Research Support, Non-U.S. Gov't | 13 | 0.0 |
Amino Acid Sequence | 6 | 0.0 |
Base Sequence | 5 | 0.0 |
Molecular Sequence Data | 6 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 7 | 0.0 |
Binding Sites | 3 | 0.0 |
Hela Cells | 11 | 0.0 |
*Nucleocytoplasmic Transport Proteins | 2 | 5.0 |
*Receptors, Cytoplasmic and Nuclear | 6 | 6.0 |
Polymerase Chain Reaction | 2 | 0.0 |
Sequence Analysis, DNA | 2 | 0.0 |
Dactinomycin/pharmacology | 2 | 0.0 |
Karyopherins | 2 | 7.0 |
Microscopy, Fluorescence | 4 | 0.0 |
*Nuclear Pore Complex Proteins | 8 | 11.0 |
Blotting, Western | 2 | 0.0 |
Cell Nucleus/*metabolism | 4 | 0.0 |
Cytoplasm/metabolism | 5 | 0.0 |
Fluorescent Antibody Technique, Indirect | 2 | 0.0 |
Glutathione Transferase/metabolism | 2 | 0.0 |
Mutagenesis, Site-Directed | 2 | 0.0 |
Precipitin Tests | 5 | 0.0 |
Protein Binding | 5 | 0.0 |
Protein Transport | 3 | 0.0 |
Recombinant Proteins/metabolism | 3 | 0.0 |
Active Transport, Cell Nucleus | 3 | 1.0 |
Animals | 12 | 0.0 |
Biological Transport | 3 | 0.0 |
Cell Division | 2 | 0.0 |
Gene Targeting | 2 | 0.0 |
Mice | 4 | 0.0 |
Mutagenesis | 3 | 0.0 |
Nuclear Pore/*metabolism | 4 | 36.0 |
Nuclear Pore Complex Proteins/genetics/*metabolism | 2 | 40.0 |
Comparative Study | 3 | 0.0 |
Sequence Homology, Amino Acid | 3 | 0.0 |
Two-Hybrid System Techniques | 2 | 0.0 |
Plasmids | 3 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 3 | 0.0 |
COS Cells | 3 | 0.0 |
Zinc Fingers | 2 | 0.0 |
Cell Nucleus/metabolism | 2 | 0.0 |
Cloning, Molecular | 2 | 0.0 |
beta Karyopherins | 2 | 13.0 |
Cell Line | 3 | 0.0 |
Point Mutation | 2 | 0.0 |
Rats | 3 | 0.0 |
Macromolecular Substances | 2 | 0.0 |
Protein Structure, Tertiary | 2 | 0.0 |
Time Factors | 2 | 0.0 |
Microscopy, Immunoelectron | 2 | 0.0 |